How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?
Would you recommend concurrent chemoradiation or targeted therapy with lorlatinib?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Michigan Medical School
Answered on
Stage IIIB encompasses T3-4N2 and T1-2N3, so I will assume that we are not going to consider a neo-adjuvant approach. Standard treatment for stage IIIB ALK+ NSCLC would be definitive concurrent chemo/RT given with curative intent. Reasonable chemo regimens would be weekly carboplatin plus paclitaxel...
Join for free or sign in to see the full answer